by Raynovich Rod | Jan 10, 2018 | Biopharmaceuticals
Sluggish Early Trading in Biotech Tracks NASDAQ Down 0.14%% Promising Year for M&A and Tax Cuts Improving Bottom Line There is a little follow-on to Tuesday’s rally bringing prices for major ETFs above where they were last week. The biotech screen reverted...
by Raynovich Rod | Jan 20, 2014 | 2023 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
2014 J.P.Morgan Healthcare Conference Update #4-Rayno Biopharmaceutical Picks Biotechnology started off with a roar and major indices were up 10% or more. Much of it can be attributed to the excitement and anticipation of the JPMorgan Conference with 10,000 attendees...
by Raynovich Rod | Dec 16, 2013 | 2023 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
But A Lot of Green Today in Diagnostics and Tools The NASDAQ (4030)and the S&P (1787) are up about 0.7% but biotech stocks are lagging with the IBB ($216) up only 0.33%. Momentum in biopharmaceutical stocks has been easing since a late November move around the...
by Rod Raynovich | Mar 11, 2011 | BIOgraph, Reading List
Hot biomedical concepts: Software, mobile communications, ophthalmology,antibiotics,epilepsy,surgery,cancer, and publishing. On Thursday March 9 The Wall Street Journal published an excellent review of the Top 50 start-ups and the money raised.The leaders were...